Clinical trials: Pregnancy, Multiple
Respiratory Tract Infections, Urinary Tract Infections
Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the…
- Trial name
- SWSB (NCT01426191)
- Testing
- xinzhijun
- Volunteers
- 2,032 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Secondary Hyperparathyroidism
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
This was a multiple-dose, double-blind, randomized, placebo-controlled study. Chinese subjects residing in Mainland China with chronic kidney disease (CKD) receiving hemodialysis were randomized in a 3:1 ratio to receive 5 mg…
- Trial name
- NCT03283098
- Testing
- Etelcalcetide
- Where
- 5 sites in China
- Volunteers
- 33 people
- Sponsor
- Amgen
Respiratory Distress Syndrome
A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants
The purpose of this study is to see if a medication called Curosurf can reduce the length of time that small premature babies with Respiratory Distress Syndrome (immature lungs) or RDS, stay on the ventilator, as compared to the…
- Trial name
- NCT01709409
- Testing
- Curosurf-Group1, BLES-group 2
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Ottawa Hospital Research Institute
Carcinoma, Carcinoma, Renal Cell
Savolitinib vs. Sunitinib in MET-driven PRCC.
This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma.
- Conditions
- Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
- Trial name
- NCT03091192
- Testing
- Savolitinib, Sunitinib
- Where
- 59 sites in United States, Brazil and 5 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.
- Trial name
- NCT03409107
- Testing
- Daprodustat (GSK1278863), Iron therapy
- Where
- 168 sites in United States, Argentina and 12 more
- Volunteers
- 614 people
- Sponsor
- GlaxoSmithKline
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Painful Bladder Syndrome, Interstitial Cystitis
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT00517868
- Testing
- URG101
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Urigen
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
- Trial name
- NCT02879305
- Testing
- Daprodustat, rhEPO, Iron therapy
- Where
- 462 sites in United States, Argentina and 33 more
- Volunteers
- 2,964 people
- Sponsor
- GlaxoSmithKline
Metastatic Renal Cell Carcinoma
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
- Trial name
- NCT01223027
- Testing
- Dovitinib, Sorafenib
- Where
- 199 sites in United States, Argentina and 25 more
- Volunteers
- 564 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease (ESRD), Diabetes
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients…
- Conditions
- End Stage Renal Disease (ESRD), Diabetes, CAPD
- Trial name
- EDEN (NCT01219959)
- Testing
- Dianeal, Dianeal, Extraneal, Nutrineal
- Where
- 16 sites in Colombia
- Volunteers
- 71 people
- Sponsor
- Vantive Health LLC
Prostate Cancer Metastatic
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of…
- Trial name
- PROfind (NCT03490032)
- Testing
- [68Ga]-PSMA-R2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Advanced Accelerator Applications
PNH
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.
- Trial name
- NCT03593200
- Testing
- Pegcetacoplan
- Where
- 3 sites in Bulgaria, Serbia
- Volunteers
- 4 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Overactive Bladder in Parkinson's Disease
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.
- Trial name
- URGE-PD (NCT01018264)
- Testing
- solifenacin succinate (VESIcare)
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of South Florida
Overactive Bladder (OAB)
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
- Trial name
- PILLAR (NCT02216214)
- Testing
- Mirabegron
- Where
- 120 sites in United States, Canada
- Volunteers
- 888 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
- Trial name
- NCT03029208
- Testing
- Daprodustat, Darbepoetin alfa, Iron therapy
- Where
- 111 sites in United States, Argentina and 13 more
- Volunteers
- 312 people
- Sponsor
- GlaxoSmithKline
Paroxysmal Nocturnal Hemoglobinuria
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received…
- Trial name
- PADDOCK (NCT02588833)
- Testing
- Pegcetacoplan
- Where
- 7 sites in Hong Kong, Malaysia and 2 more
- Volunteers
- 23 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Renal Failure, Kidney Disease
Prevention of Serious Adverse Events Following Angiography
The purpose of this research study is to compare the effectiveness of intravenous isotonic sodium bicarbonate with intravenous isotonic sodium chloride and oral N-acetylcysteine (NAC) with oral placebo for the prevention of…
- Conditions
- Acute Renal Failure, Kidney Disease, Coronary Artery Disease
- Trial name
- PRESERVE (NCT01467466)
- Testing
- IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 5,177 people
- Sponsor
- VA Office of Research and Development